News
DRRX
--
0.00%
--
Executives Buy Around $17M Of 5 Penny Stocks
The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors...
Benzinga · 2d ago
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managin...
PR Newswire · 3d ago
DURECT Corporation (NASDAQ:DRRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders might have noticed that DURECT Corporation ( NASDAQ:DRRX ) filed its quarterly result this time last week...
Simply Wall St. · 05/08 12:19
Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of 0% and 21.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:25
Durect Q1 Net Loss $10.8M, Sales $1.90M Miss $2.28M Estimate
Durect (NASDAQ:DRRX) reported quarterly sales of $1.90 million which missed the analyst consensus estimate of $2.28 million by 16.67 percent. This is a 14.10 percent decrease over sales of $2.21 million the same period
Benzinga · 05/04 20:44
Durect GAAP EPS of -$0.05 in-line, revenue of $1.92M misses by $0.36M
Durect press release (NASDAQ:DRRX): Q1 GAAP EPS of -$0.05 in-line. Revenue of $1.92M (-13.1% Y/Y) misses by $0.36M.
Seekingalpha · 05/04 20:17
Earnings Outlook For Durect
Durect (NASDAQ:DRRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Durect will report an earnings per share (EPS) of $-0.05.
Benzinga · 05/03 20:43
DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4
DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022.
PR Newswire · 04/27 20:15
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.
Benzinga · 04/25 08:23
Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock?
Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks · 03/24 13:30
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, will be participating in a panel discussion at the Cantor Virtual Rare Orphan Disease Summit hosted by Kristen Kluska, Managing Director, Biotechnology Research A...
PR Newswire · 03/23 20:15
Imago BioSciences Names Laura Eichorn CFO, Michael Arenberg Chief Operating Officer
MT Newswires · 03/23 18:03
As DURECT Corporation's (NASDAQ:DRRX) market cap increased US$26m, insiders who bought last year may be reflecting on buying more
Last week, DURECT Corporation ( NASDAQ:DRRX ) insiders, who had purchased shares in the previous 12 months were...
Simply Wall St. · 03/23 17:29
Insider Buy: Durect
MT Newswires · 03/16 15:02
DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. WeiQi Lin, Executive Vice President of R&D and Dr. Norman Sussman, Chief Medical Officer, will be participating in a fireside chat hosted by Francois Briseboi...
PR Newswire · 03/09 21:30
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
Durect (DRRX) delivered earnings and revenue surprises of 40% and 204.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 03/07 22:25
BRIEF-Durect Corporation Qtrly Net Loss Per Common Share, Basic And Diluted $0.03
reuters.com · 03/07 21:14
Durect Q4 EPS $(0.03) Beats $(0.05) Estimate, Sales $7.30M Beat $2.10M Estimate
Durect (NASDAQ:DRRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 25 percent increase over losses of $(0.04) per share from the same period
Benzinga · 03/07 21:09
Durect GAAP EPS of -$0.03 beats by $0.02, revenue of $7.3M beats by $5.2M
Durect press release (NASDAQ:DRRX): Q4 GAAP EPS of -$0.03 beats by $0.02. Revenue of $7.3M (+230.3% Y/Y) beats by $5.2M. At December 31, 2021, cash and investments were $70.0 million
Seekingalpha · 03/07 21:06
Durect defended at H.C. Wainwright after resignation of CFO
The clinical-stage pharma company, Durect Corporation (DRRX -3.9%) is trading lower for the fourth straight session on Monday as the investors react to the resignation of its Chief Financial Officer,
Seekingalpha · 03/07 20:20
Webull provides a variety of real-time DRRX stock news. You can receive the latest news about DURECT through multiple platforms. This information may help you make smarter investment decisions.
About DRRX
DURECT Corporation is a biopharmaceutical company focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. DUR‑928 is a candidate in its Epigenetic Regulator Program. Injectable DUR-928 is under testing in a Phase II clinical trial and oral DUR-928 is under testing in a Phase I clinical trial. The chronic toxicity of DUR-928 was further assessed in a 6-month oral study in rats and in a 9-month oral study in dogs. POSIMIR enabling continuous sustained delivery of bupivacaine, a non-opioid local analgesic, over 3 days in adults to control post-surgical pain of patients.